Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.
Kooyman A, Chang JS, Liu M, Jiang W, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson R, Baker S.
Kooyman A, et al. Among authors: pai h.
Int J Radiat Oncol Biol Phys. 2025 Apr 10:S0360-3016(25)00347-5. doi: 10.1016/j.ijrobp.2025.03.079. Online ahead of print.
Int J Radiat Oncol Biol Phys. 2025.
PMID: 40216089